A case of systemic contact dermatitis associated with a peritoneal dialysis catheter and treated with dupilumab.

IF 0.7 Q4 UROLOGY & NEPHROLOGY
CEN Case Reports Pub Date : 2025-06-01 Epub Date: 2025-03-07 DOI:10.1007/s13730-025-00980-9
Kosuke Mochizuki, Jun Takeoka, Naohiro Toda, Kansei Otsuka, Ryo Sato, Satoshi Kurahashi, Kyoka Fujita, Hisako Hirashima, Akira Ishii, Toshiyuki Komiya
{"title":"A case of systemic contact dermatitis associated with a peritoneal dialysis catheter and treated with dupilumab.","authors":"Kosuke Mochizuki, Jun Takeoka, Naohiro Toda, Kansei Otsuka, Ryo Sato, Satoshi Kurahashi, Kyoka Fujita, Hisako Hirashima, Akira Ishii, Toshiyuki Komiya","doi":"10.1007/s13730-025-00980-9","DOIUrl":null,"url":null,"abstract":"<p><p>Eosinophilia during the induction of peritoneal dialysis (PD) is frequently caused by icodextrin, but allergic reactions to PD catheters have been rarely reported. In previous reports, PD catheter-induced systemic contact dermatitis in patients undergoing PD sometimes required catheter removal, therefore there is a need to consider alternative renal replacement therapies other than PD. Here, we report a case of systemic contact dermatitis associated with a PD catheter that was successfully treated with dupilumab, avoiding catheter removal. The 62-year-old man undergoing PD had eosinophilia and pruritic skin rash after PD catheter implantation and was diagnosed with systemic contact dermatitis triggered by silicon contained in the catheter. Even though low doses of steroids were introduced, skin symptoms and eosinophilia were not controlled. After initiation of dupilumab treatment, skin pruritus was improved, and eosinophils also decreased. Although dupilumab use is expanding for systemic contact dermatitis, no previous reports of dupilumab administration in dialysis patients have been reported. This case is the first of a patient undergoing PD and using dupilumab for systemic contact dermatitis caused by a PD catheter, in which dupilumab successfully controlled skin rash and pruritus eosinophilia. Dupilumab is, therefore, a favorable option for treating systemic contact dermatitis induced by a PD catheter as an alternative to steroids and removal of the PD catheter.</p>","PeriodicalId":9697,"journal":{"name":"CEN Case Reports","volume":" ","pages":"450-454"},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CEN Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13730-025-00980-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Eosinophilia during the induction of peritoneal dialysis (PD) is frequently caused by icodextrin, but allergic reactions to PD catheters have been rarely reported. In previous reports, PD catheter-induced systemic contact dermatitis in patients undergoing PD sometimes required catheter removal, therefore there is a need to consider alternative renal replacement therapies other than PD. Here, we report a case of systemic contact dermatitis associated with a PD catheter that was successfully treated with dupilumab, avoiding catheter removal. The 62-year-old man undergoing PD had eosinophilia and pruritic skin rash after PD catheter implantation and was diagnosed with systemic contact dermatitis triggered by silicon contained in the catheter. Even though low doses of steroids were introduced, skin symptoms and eosinophilia were not controlled. After initiation of dupilumab treatment, skin pruritus was improved, and eosinophils also decreased. Although dupilumab use is expanding for systemic contact dermatitis, no previous reports of dupilumab administration in dialysis patients have been reported. This case is the first of a patient undergoing PD and using dupilumab for systemic contact dermatitis caused by a PD catheter, in which dupilumab successfully controlled skin rash and pruritus eosinophilia. Dupilumab is, therefore, a favorable option for treating systemic contact dermatitis induced by a PD catheter as an alternative to steroids and removal of the PD catheter.

1例与腹膜透析导管相关的系统性接触性皮炎,用杜匹单抗治疗。
腹膜透析(PD)诱导过程中嗜酸性粒细胞增多常由icodextrin引起,但对PD导管的过敏反应很少报道。在以往的报道中,PD患者由PD导管引起的全身性接触性皮炎有时需要拔除导管,因此需要考虑PD以外的其他肾脏替代疗法。在这里,我们报告了一例全身接触性皮炎与PD导管相关的病例,该病例成功地用dupilumab治疗,避免了导管的移除。62岁男性PD患者在PD导管植入后出现嗜酸性粒细胞增多和瘙痒性皮疹,并被诊断为全身接触性皮炎,由导管中含有的硅引起。即使使用了低剂量的类固醇,皮肤症状和嗜酸性粒细胞增多也没有得到控制。开始dupilumab治疗后,皮肤瘙痒得到改善,嗜酸性粒细胞也减少。虽然杜匹单抗在全身性接触性皮炎中的应用正在扩大,但此前没有关于透析患者使用杜匹单抗的报道。该病例是首例接受PD治疗并使用杜匹单抗治疗PD导管引起的系统性接触性皮炎的患者,杜匹单抗成功控制了皮疹和瘙痒性嗜酸性粒细胞增多症。因此,Dupilumab是治疗PD导管引起的系统性接触性皮炎的一个有利选择,可以替代类固醇和PD导管的移除。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CEN Case Reports
CEN Case Reports UROLOGY & NEPHROLOGY-
CiteScore
1.90
自引率
0.00%
发文量
80
期刊介绍: Clinical and Experimental Nephrology (CEN) Case Reports is a peer-reviewed online-only journal, officially published biannually by the Japanese Society of Nephrology (JSN).  The journal publishes original case reports in nephrology and related areas.  The purpose of CEN Case Reports is to provide clinicians and researchers with a forum in which to disseminate their personal experience to a wide readership and to review interesting cases encountered by colleagues all over the world, from whom contributions are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信